Alimera Sciences Net Income 2009-2021 | ALIM

Alimera Sciences net income from 2009 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Alimera Sciences Annual Net Income
(Millions of US $)
2020 $-5
2019 $-10
2018 $22
2017 $-22
2016 $-33
2015 $-31
2014 $-37
2013 $-51
2012 $-20
2011 $-23
2010 $-17
2009 $-52
2008 $-69
Alimera Sciences Quarterly Net Income
(Millions of US $)
2021-09-30 $-4
2021-06-30 $8
2021-03-31 $-4
2020-12-31 $-1
2020-09-30 $-1
2020-06-30 $-3
2020-03-31 $-1
2019-12-31 $0
2019-09-30 $-3
2019-06-30 $-5
2019-03-31 $-3
2018-12-31 $-1
2018-09-30 $35
2018-06-30 $-4
2018-03-31 $-8
2017-12-31 $-7
2017-09-30 $-5
2017-06-30 $-3
2017-03-31 $-7
2016-12-31 $-6
2016-09-30 $-9
2016-06-30 $-7
2016-03-31 $-11
2015-12-31 $-11
2015-09-30 $-2
2015-06-30 $-9
2015-03-31 $-10
2014-12-31 $-10
2014-09-30 $-7
2014-06-30 $1
2014-03-31 $-21
2013-12-31 $-15
2013-09-30 $-1
2013-06-30 $-21
2013-03-31 $-14
2012-12-31 $-5
2012-09-30 $-5
2012-06-30 $-5
2012-03-31 $-4
2011-12-31 $-6
2011-09-30 $-7
2011-06-30 $-5
2011-03-31 $-5
2010-12-31 $-6
2010-09-30 $-6
2010-06-30 $-5
2010-03-31 $0
2009-12-31 $-23
2009-09-30 $-7
2009-06-30 $-8
2009-03-31 $-12
2008-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.032B $0.051B
Alimera Sciences, Inc., based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company is presently focused on diseases affecting the back of the eye, or retina because it believes these diseases are not well treated with current therapies and represent a significant market opportunity. Its product candidate Iluvien(R) is an intravitreal insert containing fluocinolone acetonide, a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. Iluvien is in development for the treatment of diabetic macular edema (DME). DME is a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $143.345B 9.06
Bio-Rad Laboratories (BIO.B) United States $18.101B 36.73
QIAGEN (QGEN) Netherlands $11.301B 19.14
Biohaven Pharmaceutical Holding (BHVN) United States $7.598B 0.00
Emergent Biosolutions (EBS) United States $2.503B 9.00
Arcus Biosciences (RCUS) United States $2.274B 0.00
Myovant Sciences (MYOV) United Kingdom $1.296B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.081B 0.00
Zymeworks (ZYME) Canada $0.538B 0.00
SQZ Biotechnologies (SQZ) United States $0.203B 0.00
Ambrx Biopharma (AMAM) United States $0.201B 0.00
Enzo Biochem (ENZ) United States $0.155B 20.00